CoChat

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

Open access
Fernández Montes, Ana, Alonso Orduña, Vicente, Asensio Martínez, Elena, Rodríguez Salas, Nuria, Torres, Esperanza, Cacho Lavín, Diego, Rodríguez Alonso, Rosa María, Falcó, Esther, Oliva, Joan Carles, Cirera, Lluis, García Gómez, Jesus, Pericay, Carles · 2023 · The Oncologist

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Background: Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the mutation. This multicenter, retrospective, cohort study assessed the frequency and prognostic value of specific KRAS mutation codon locations in mCRC patients, and survival outcomes in relation to treatment. Materials and Methods: Data from mCRC patients treated in 10 Spanish hospitals between January 2011 and December 2015 were analyzed. The main objective was to investigate (1) the impact of KRAS mutation location on overall survival (OS), and (2) the effect of targeted treatment plus metastasectomy and primary tumor location on OS in patients with KRAS mutations. Results: The KRAS mutation location was known for 337/2002 patients. Of these, 177 patients received chemotherapy only, 155 received bevacizumab plus chemotherapy, and 5 received anti-epidermal growth factor receptor therapy plus chemotherapy; 94 patients underwent surgery. The most frequent KRAS mutation locations were G12A (33.8%), G12D (21.4%), and G12V (21.4%). Compared with other locations, patients with a G12S mutation had the shortest median OS (10.3 [95% CI, 2.5-18.0] months). OS was longer in patients who underwent surgery versus those who did not, with a trend toward prolonged survival with bevacizumab (median OS 26.7 [95% CI, 21.8-31.7] months) versus chemotherapy alone (median OS 23.2 [95% CI, 19.4-27.0] months). Conclusion: These findings confirm that KRAS mutation location may predict survival outcomes in patients with mCRC, and suggest that pre-/post-operative bevacizumab plus metastasectomy provides survival benefits in patients with KRAS mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/oncolo/oyad117

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study design and patient distribution. Abbreviations: EGFR, endothelial growth factor receptor; mKRAS, mutated V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; pts, patients; VEGF, vascular endothelial growth factor.
Figure 1. Study design and patient distribution. Abbreviations: EGFR, endothelial growth factor receptor; mKRAS, mutated V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; pts, patients; VEGF, vascular endothelial growth factor.CC BY · PubMed Central
Figure 2. Kaplan-Meier analysis of overall survival by treatment. aData from patients treated with anti-EGFR (n = 5) were not analyzed by treatment or surgery. Abbreviations: EGFR, endothelial growth factor receptor; OS, overall survival; VEGF, vascular endothelial growth factor.
Figure 2. Kaplan-Meier analysis of overall survival by treatment. aData from patients treated with anti-EGFR (n = 5) were not analyzed by treatment or surgery. Abbreviations: EGFR, endothelial growth factor receptor; OS, overall survival; VEGF, vascular endothelial growth factor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 19

Metadata

Authors
Fernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., García Gómez, J., & Pericay, C.
Affiliations
  • Servicio de Oncología Médica, Complexo Hospitalario Universitario de Ourense , Calle Ramón Puga Noguerol, Ourense , Spain
  • Servicio de Oncología Médica, Hospital Universitario Miguel Servet, Instituto de Investigacion Sanitaria de Aragon , Paseo Isabel la Católica, Zaragoza , Spain
  • Servicio de Oncología Médica, Hospital General Universitario de Elche , Carrer Almazara, Elche, Alicante , Spain
  • Servicio de Oncología Médica, Hospital Universitario La Paz , Paseo de la Castellana, Madrid , Spain
  • Instituto de Investigación Biomédica de Málaga (ES)
  • Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla , Santander, Cantabria , Spain
  • Servicio de Oncología Médica, Hospital Universitario Reina Sofía-Córdoba , Avenida Menéndez Pidal, Córdoba , Spain
  • Hospital Son Llatzer (ES)
  • Institute of Research and Innovation Parc Tauli (ES)
  • University Hospital Mútua de Terrassa (ES)
  • Corporació Sanitària Parc Taulí (ES)
Venue
The Oncologist
Published
2023-05-04
Volume
28
Issue
10
Pages
e902-e909
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W4368342849
Cited by
17
References
27
Citations by year
2026: 7 · 2025: 5 · 2024: 4 · 2023: 1
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by)
  • Hispana (submittedVersion, cc-by)
Funders
  • Merck
  • Merck KGaA
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, metastatic colorectal cancer, overall survival, bevacizumab, metastasectomy, anti-EGFR therapy, chemotherapy, prognostic factors, treatment selection
MeSH terms
Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Mutation, Prognosis, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Cohort Studies, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.